20
What are the latest advances in Sarcoidosis?
Here you can see the latest advances and discoveries made regarding Sarcoidosis.
Not too many. Though there is no known cure there are medicines that can help treat your symptoms. Pain meds, anxiety and depression meds, immunosupressant meds, etc. some say cbd oil can help as well as a nicotine patch helping. However more research and studies need to be done.
Posted Sep 7, 2017 by Kristie 2000
It seems a Cancer drugs are working to help control the sarcoid problems. Humera helps with the osteoporosis which also seems to keep the sarcoidosis symptoms at Bay. Prednisone helps a lot in the beginning and sometimes you can be weaned off of it or it could be a lifelong medication.
Posted Sep 11, 2017 by XTIENNA 2000
Sarcoidosis treatments are being researched more widely around the world due to the numbers of patients being diagnosed increasing. However funding for research is not easily come by. Support groups are increasing awareness of the disease and various voluntary organisations are fund raising for further research and support for patients. Advice is to find the best possible specialist who has experience in the disease even if you have to travel a substantial distance to be seen.
Posted Oct 26, 2017 by Diane 2735
Sarcoidosis News
Skip to content
HOME
ABOUT US
Search for:
Search
TNF Antagonists Are Effective at Treating Sarcoidosis, but Adverse Events Are a Concern
OCTOBER 3, 2017 Iqra Mumal, PhDBY IQRA MUMAL, PHD
TNF Antagonists Are Effective at Treating Sarcoidosis, but Adverse Events Are a Concern
Tumor necrosis factor (TNF) antagonists are effective therapies in a significant proportion of patients with severe and refractory sarcoidosis, a new study shows. However, they also are associated with adverse events such as infections and allergic reactions.
The study titled, “Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: A multicenter study of 132 patients,” was published in the journal Seminars in Arthritis and Rheumatism.
Drugs that target TNF have been studied as potential therapeutic agents for sarcoidosis.
Prior studies have indicated that TNF plays a role in the inflammatory processes that characterized sarcoidosis. Alveolar macrophages, which are immune cells of the lungs, release TNF in patients with active lung disease.
However, the use of TNF antagonists has been associated with several adverse events, infections, and malignancies.
The off-label use of TNF antagonists in the treatment of refractory sarcoidosis is increasing, despite the fact that data on their efficacy and safety in this patient population are still lacking.
In order to address this question, researchers investigated the effectiveness and safety of two TNF antagonists – infliximab and adalimumab – in sarcoidosis patients.
The team retrospectively analyzed 132 sarcoidosis patients who received treatment with infliximab (91%) or adalimumab (6%).
Researchers found that approximately two-thirds (64%) of patients had either a complete or partial response to treatment with a TNF antagonist, particularly patients whose brain, heart, skin, and upper respiratory tract were affected by the disease.
No differences in effectiveness were found among patients using anti-TNF and patients using anti-TNF combined with immunosuppressant agents.
Furthermore, patients using TNF antagonists required a lower dose of prednisone, a corticosteroid prescribed in sarcoidosis patients, at the end of the follow-up period.
In total, 52% of the patients assessed experienced adverse events, with the most frequent being infections (36% of patients) and allergic reactions (8%).
Treatment interruption due to adverse events or because it was not working was reported in 23% of the patients. Among these patients, 13 relapsed within 14 months, on average. Patients receiving anti-TNF therapies are known to be at risk of relapse during treatment or after drug withdrawal.
Researchers also found that “pulmonary involvement was associated with a lower clinical response to anti-TNF” in patients with sarcoidosis.
Overall, “the present study has demonstrated TNF-antagonist efficiency in the majority of patients though infections and relapses rates were rather high in long-lasting and long-treated cases,” the team concluded.
Print Friendly, PDF & Email
TAGGED ADALIMUMAB, ADVERSE EVENTS, ANTAGONISTS, INFECTIONS, INFLIXIMAB, RELAPSE, TNF, TUMOR NECROSIS FACTOR.
Iqra Mumal, PhD
Iqra Mumal, PhD
Post navigation
Cardiac sarcoidosis cases
PREVIOUS:
Cardiac Sarcoidosis Cases Doubled in US from 2005-2011, Study Finds
FDA rare diseases grant
NEXT:
FDA Awards $300,000 Grant to University of Iowa Researcher for Sarcoidosis Study
Leave a Comment
Your email address will not be published. Required fields are marked *
Comment
Name *
Email *
Website
Post Comment
Notify me of follow-up comments by email.
Notify me of new posts by email.
Search for:
Search
Get our FREE Newsletter
* indicates required
Email Address *
First Name
Last Name
Subscribe
Recent Sarcoidosis Articles
NORD SUMMIT
#NORDsummit – Alternatives to Large Placebo Trials, Grant Awards Among Ways FDA Supporting Rare Diseases, Chief Says
OCTOBER 23, 2017
sarcoidosis rare combo
Rare Case of Pancreatic, Pulmonary, and Bronchial Sarcoidosis Reported
OCTOBER 19, 2017
ODA report
#NORDsummit – Despite Criticism, Orphan Drug Act Is Working to Advance Needed Treatments, FDA Says
OCTOBER 19, 2017
FDA rare diseases grant
FDA Awards $300,000 Grant to University of Iowa Researcher for Sarcoidosis Study
OCTOBER 17, 2017
TNF antagonists
TNF Antagonists Are Effective at Treating Sarcoidosis, but Adverse Events Are a Concern
OCTOBER 3, 2017
Sarcoidosis News
Follow On
Sarcoidosis News
BioNews Services, LLC
5307 E. Mockingbird Ln.
5th Floor
Dallas, TX 75206
Email: [email protected]
Phone: 1-800-936-1363
Recent Posts
NORD SUMMIT
#NORDsummit – Alternatives to Large Placebo Trials, Grant Awards Among Ways FDA Supporting Rare Diseases, Chief Says
OCTOBER 23, 2017
sarcoidosis rare combo
Rare Case of Pancreatic, Pulmonary, and Bronchial Sarcoidosis Reported
OCTOBER 19, 2017
ODA report
#NORDsummit – Despite Criticism, Orphan Drug Act Is Working to Advance Needed Treatments, FDA Says
OCTOBER 19, 2017
FDA rare diseases grant
FDA Awards $300,000 Grant to University of Iowa Researcher for Sarcoidosis Study
OCTOBER 17, 2017
About Us
Contact Us
Terms of Service
Privacy Policy
Disclaimer:
Sarcoidosis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Copyright © 2013-2017 All rights reserved.
Skip to content
HOME
ABOUT US
Search for:
Search
TNF Antagonists Are Effective at Treating Sarcoidosis, but Adverse Events Are a Concern
OCTOBER 3, 2017 Iqra Mumal, PhDBY IQRA MUMAL, PHD
TNF Antagonists Are Effective at Treating Sarcoidosis, but Adverse Events Are a Concern
Tumor necrosis factor (TNF) antagonists are effective therapies in a significant proportion of patients with severe and refractory sarcoidosis, a new study shows. However, they also are associated with adverse events such as infections and allergic reactions.
The study titled, “Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: A multicenter study of 132 patients,” was published in the journal Seminars in Arthritis and Rheumatism.
Drugs that target TNF have been studied as potential therapeutic agents for sarcoidosis.
Prior studies have indicated that TNF plays a role in the inflammatory processes that characterized sarcoidosis. Alveolar macrophages, which are immune cells of the lungs, release TNF in patients with active lung disease.
However, the use of TNF antagonists has been associated with several adverse events, infections, and malignancies.
The off-label use of TNF antagonists in the treatment of refractory sarcoidosis is increasing, despite the fact that data on their efficacy and safety in this patient population are still lacking.
In order to address this question, researchers investigated the effectiveness and safety of two TNF antagonists – infliximab and adalimumab – in sarcoidosis patients.
The team retrospectively analyzed 132 sarcoidosis patients who received treatment with infliximab (91%) or adalimumab (6%).
Researchers found that approximately two-thirds (64%) of patients had either a complete or partial response to treatment with a TNF antagonist, particularly patients whose brain, heart, skin, and upper respiratory tract were affected by the disease.
No differences in effectiveness were found among patients using anti-TNF and patients using anti-TNF combined with immunosuppressant agents.
Furthermore, patients using TNF antagonists required a lower dose of prednisone, a corticosteroid prescribed in sarcoidosis patients, at the end of the follow-up period.
In total, 52% of the patients assessed experienced adverse events, with the most frequent being infections (36% of patients) and allergic reactions (8%).
Treatment interruption due to adverse events or because it was not working was reported in 23% of the patients. Among these patients, 13 relapsed within 14 months, on average. Patients receiving anti-TNF therapies are known to be at risk of relapse during treatment or after drug withdrawal.
Researchers also found that “pulmonary involvement was associated with a lower clinical response to anti-TNF” in patients with sarcoidosis.
Overall, “the present study has demonstrated TNF-antagonist efficiency in the majority of patients though infections and relapses rates were rather high in long-lasting and long-treated cases,” the team concluded.
Print Friendly, PDF & Email
TAGGED ADALIMUMAB, ADVERSE EVENTS, ANTAGONISTS, INFECTIONS, INFLIXIMAB, RELAPSE, TNF, TUMOR NECROSIS FACTOR.
Iqra Mumal, PhD
Iqra Mumal, PhD
Post navigation
Cardiac sarcoidosis cases
PREVIOUS:
Cardiac Sarcoidosis Cases Doubled in US from 2005-2011, Study Finds
FDA rare diseases grant
NEXT:
FDA Awards $300,000 Grant to University of Iowa Researcher for Sarcoidosis Study
Leave a Comment
Your email address will not be published. Required fields are marked *
Comment
Name *
Email *
Website
Post Comment
Notify me of follow-up comments by email.
Notify me of new posts by email.
Search for:
Search
Get our FREE Newsletter
* indicates required
Email Address *
First Name
Last Name
Subscribe
Recent Sarcoidosis Articles
NORD SUMMIT
#NORDsummit – Alternatives to Large Placebo Trials, Grant Awards Among Ways FDA Supporting Rare Diseases, Chief Says
OCTOBER 23, 2017
sarcoidosis rare combo
Rare Case of Pancreatic, Pulmonary, and Bronchial Sarcoidosis Reported
OCTOBER 19, 2017
ODA report
#NORDsummit – Despite Criticism, Orphan Drug Act Is Working to Advance Needed Treatments, FDA Says
OCTOBER 19, 2017
FDA rare diseases grant
FDA Awards $300,000 Grant to University of Iowa Researcher for Sarcoidosis Study
OCTOBER 17, 2017
TNF antagonists
TNF Antagonists Are Effective at Treating Sarcoidosis, but Adverse Events Are a Concern
OCTOBER 3, 2017
Sarcoidosis News
Follow On
Sarcoidosis News
BioNews Services, LLC
5307 E. Mockingbird Ln.
5th Floor
Dallas, TX 75206
Email: [email protected]
Phone: 1-800-936-1363
Recent Posts
NORD SUMMIT
#NORDsummit – Alternatives to Large Placebo Trials, Grant Awards Among Ways FDA Supporting Rare Diseases, Chief Says
OCTOBER 23, 2017
sarcoidosis rare combo
Rare Case of Pancreatic, Pulmonary, and Bronchial Sarcoidosis Reported
OCTOBER 19, 2017
ODA report
#NORDsummit – Despite Criticism, Orphan Drug Act Is Working to Advance Needed Treatments, FDA Says
OCTOBER 19, 2017
FDA rare diseases grant
FDA Awards $300,000 Grant to University of Iowa Researcher for Sarcoidosis Study
OCTOBER 17, 2017
About Us
Contact Us
Terms of Service
Privacy Policy
Disclaimer:
Sarcoidosis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Copyright © 2013-2017 All rights reserved.
Posted Oct 27, 2017 by KindredSpirit 2050
Current research is focasinv on bacterial or viral triggers although it is believed that environmental factors may also have an influence
Posted Oct 27, 2017 by Wendy 2000
Many hospitals around the world are doing research into what can trigger sarcoid
Different medicaton is being developed all the time but as of yet nothing CA's been confirmed to work in totally easing symptoms
Research still has a long way to go before a cure is found
Different medicaton is being developed all the time but as of yet nothing CA's been confirmed to work in totally easing symptoms
Research still has a long way to go before a cure is found
Posted Oct 27, 2017 by Stewart 2000
There are no latest advances, promote awareness
Posted Mar 31, 2018 by Cathleen 1900
There are many studies being done on sarcoidosis several of them in the UK and Britain. Corticosteroids are still used to treat most sarcoidosis flares. Some studies suggest that only 20% of all sarcoidosis cases need to be treated. There's much information to be read on treatments and much to discuss with your doctor when she using the proper treatment for you.
Posted Jul 4, 2018 by msinky 2550
Isolation of a gene called Amyloid A found in Sarcoidosis sufferers .
New intravenous drug options in America but South Africa to date only prescribes prednisone or methotrexate
New intravenous drug options in America but South Africa to date only prescribes prednisone or methotrexate
Posted Oct 15, 2018 by Zaida 1050
New medications txts
Posted Oct 8, 2019 by Lashawn 2500
I'm on remicaid and cell cept They are working on new medications
Posted Mar 8, 2020 by Elizabeth 4800
Advancements are happening all the time via Doctor to Doctor or even Patient to Doctor. I am seen at National Jewish Health by a team. I have neurological, pulmonary, heart, muscular, and lymph node involvement. Six years ago when I was a new patient I only had Pulmonary and Lymph Node involvement but my disease has progressed. When my heart started to give me issues I did my own research and brought what I found to my doctor visits. They took what I bought and are now doing their own research into it's findings. Don't give up and be an advocate for yourself, as no one else will.
Posted Jan 18, 2021 by Althea 4550
I started on COPD Herbal treatment from Ultimate Health Home, the treatment worked incredibly for my lungs condition. I used the herbal treatment for almost 4 months, it reversed my COPD. My severe shortness of breath, dry cough, chest tightness gradually disappeared. Reach Ultimate Health Home via their email at [email protected] . I can breath much better and It feels comfortable!
Posted Apr 5, 2021 by Robert 9039
A new drug, Ofev (nintedanib) has been approved by the Food and Drug Administration to slow the progression interstitial lung disease.
Posted Sep 14, 2023 by Emma Johnson 2500
